Cargando…

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516048/ https://www.ncbi.nlm.nih.gov/pubmed/26003617 http://dx.doi.org/10.1093/annonc/mdv155

Ejemplares similares

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
por: Smith, M. R., et al.
Publicado: (2015)

Cost-effectiveness Analysis of Denosumab in the Prevention of Skeletal-related Events in Patients with Prostate Cancer in Kazakhstan
por: Bektur, Carina, et al.
Publicado: (2014)

The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University Hospitals
por: Satoh, Takefumi, et al.
Publicado: (2018)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
por: Kawai, Alison Tse, et al.
Publicado: (2019)

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
por: Saad, F, et al.
Publicado: (2017)

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
por: Devitt, Bianca, et al.
Publicado: (2008)

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
por: Dranitsaris, George, et al.
Publicado: (2012)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Direct effects of doxorubicin on skeletal muscle contribute to fatigue
por: van Norren, K, et al.
Publicado: (2009)

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer
por: Idota, Ai, et al.
Publicado: (2016)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Publicado: (2018)

Corrigendum to “Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement”
por: Fouda, Mona A., et al.
Publicado: (2017)

Expression and role of lncRNAs in the regeneration of skeletal muscle following contusion injury
por: Zheng, Lifang, et al.
Publicado: (2020)

Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2022)

Bone metastases and skeletal-related events from neuroendocrine tumors
por: Van Loon, Katherine, et al.
Publicado: (2015)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
por: Zhang, Chi, et al.
Publicado: (2018)

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
por: Polascik, Thomas J
Publicado: (2009)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis
por: Hussain, Arif, et al.
Publicado: (2016)

A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases
por: Myint, Zin W., et al.
Publicado: (2022)

Health state utilities for skeletal-related events secondary to bone metastases
por: Matza, Louis S., et al.
Publicado: (2013)

Skeletal complications in acromegaly
por: Wydra, Arnika, et al.
Publicado: (2023)

Canonical Wnt signalling regulates nuclear export of Setdb1 during skeletal muscle terminal differentiation
por: Beyer, Sophie, et al.
Publicado: (2016)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
por: Shariftabrizi, Ahmad, et al.
Publicado: (2023)

Clinicopathologic characteristics, metastasis-free survival, and skeletal-related events in 628 patients with skeletal metastases in a tertiary orthopedic and trauma center
por: Herget, Georg, et al.
Publicado: (2021)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
por: Miki, Hirokazu, et al.
Publicado: (2022)

Bone resorption predicts for skeletal complications in metastatic bone disease
por: Brown, J E, et al.
Publicado: (2003)

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
por: Berruti, A, et al.
Publicado: (2005)

Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
por: Tong, Tongyu, et al.
Publicado: (2020)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_to2aj9fdj61o5bqmne71d057fn